Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB)
· seekingalpha.com
Pacific Biosciences reported Q2 revenues of $39.01M, missing estimates and guiding 2026 revenues down, below consensus. Read why PACB stock is a Sell.
After the bell on Wednesday, we received second quarter results from Pacific Biosciences ( PACB ). The sequencing solutions company has been one of the most dis...